



Solutions

**FCC Part 1 Subpart I
FCC Part 2 Subpart J**

RF EXPOSURE REPORT

FOR

Contour Plus BLUE Blood Glucose Monitoring System

MODEL NAME: 7035 and 7036

FCC ID: VN5-CPB

REPORT NUMBER: R14622069-E1

ISSUE DATE: 2024-08-26

Prepared for
Ascensia Diabetes Care Holdings AG
Peter Merian-Strasse 90 4052
Basel, Switzerland

Prepared by
UL LLC
12 LABORATORY DR.
RESEARCH TRIANGLE PARK, NC 27709 USA
TEL: (919) 549-1400



Revision History

| Rev. | Issue Date | Revisions | Revised By |
|------|------------|--------------------------------------------------------------------------------------|---------------|
| V1 | 2023-06-23 | Initial Issue | Charles Moody |
| V2 | 2024-08-26 | Revised: Added model designations 7035 and 7036 with a model difference explanation. | Jeff Moser |

TABLE OF CONTENTS

| | |
|-------------------------------------------------------------|----------|
| 1. ATTESTATION OF TEST RESULTS..... | 4 |
| 2. TEST METHODOLOGY | 5 |
| 3. REFERENCES | 5 |
| 4. FACILITIES AND ACCREDITATION..... | 5 |
| 5. DECISION RULES AND MEASUREMENT UNCERTAINTY..... | 6 |
| 5.1. <i>METROLOGICAL TRACEABILITY.....</i> | 6 |
| 5.2. <i>DECISION RULES.....</i> | 6 |
| 6. DEVICE UNDER TEST | 6 |
| 7. STANDALONE SAR TEST EXCLUSION CONSIDERATIONS..... | 7 |
| 7.1. <i>FCC.....</i> | 7 |

1. ATTESTATION OF TEST RESULTS

COMPANY NAME: Ascensia Diabetes Care Holdings AG
Peter Merian-Strasse 90 4052
Basel, Switzerland

EUT DESCRIPTION: Contour Plus BLUE Blood Glucose Monitoring System

MODEL NAME: 7035 and 7036

SERIAL NUMBER: P403802

SAMPLE RECEIVED DATE: 2023-05-31

DATE TESTED: 2023-06-05

| APPLICABLE STANDARDS | |
|-----------------------------------------|--------------|
| STANDARD | TEST RESULTS |
| FCC PART 1 SUBPART I & PART 2 SUBPART J | Complies |

UL LLC tested the above equipment in accordance with the requirements set forth in the above standards. The test results show that the equipment tested is capable of demonstrating compliance with the requirements as documented in this report.

The results documented in this report apply only to the tested sample, under the conditions and modes of operation as described herein. It is the manufacturer's responsibility to assure that additional production units of this model are manufactured with identical electrical and mechanical components. All samples tested were in good operating condition throughout the entire test program. Measurement Uncertainties are published for informational purposes only and were not taken into account unless noted otherwise.

This document may not be altered or revised in any way unless done so by UL LLC and all revisions are duly noted in the revisions section. Any alteration of this document not carried out by UL LLC will constitute fraud and shall nullify the document.

Approved & Released
For UL LLC By:



Reviewed By:



Prepared By:



Michael Antola
Staff Engineer
Consumer, Medical and IT Segment
UL LLC

Brian Kiewra
Project Engineer
Consumer, Medical and IT Segment
UL LLC

Charles Moody and Jeff Moser
Engineer and Operations Manager
Consumer, Medical and IT Segment
UL LLC

2. TEST METHODOLOGY

All calculations were made in accordance with FCC Parts 1.1310, 2.1091, 2.1093, KDB 447498 D01 v06, KDB 447498 D03 V01, IEEE Std C95.1-2005, and IEEE Std C95.3-2002.

This report contains data provided by the customer which can impact the validity of results. UL LLC is only responsible for the validity of results after the integration of the data provided by the customer

Client Provided Data:

- 1.) Max Declared Avg. Output Power (see section 7.1)

3. REFERENCES

Declared maximum average output power is excerpted from client documentation.

4. FACILITIES AND ACCREDITATION

UL LLC is accredited by A2LA, certification #0751.06, for all testing performed within the scope of this report. Testing was performed at the locations noted below.

| | Address | ISED CABID | ISED Company Number | FCC Registration |
|-------------------------------------|-----------------------------------------------------------------------------|------------|---------------------|------------------|
| <input checked="" type="checkbox"/> | Building 2800 Perimeter Park Dr. Suite B Morrisville, NC 27560, U.S.A | US0067 | 27265 | 825374 |
| <input type="checkbox"/> | Building: 12 Laboratory Dr RTP, NC 27709, U.S.A | | 2180C | |

5. DECISION RULES AND MEASUREMENT UNCERTAINTY

5.1. METROLOGICAL TRACEABILITY

The measuring equipment utilized to perform the tests documented in this report has been calibrated in accordance with the manufacturer's recommendations, and is traceable to recognized national standards.

5.2. DECISION RULES

For all tests where the applicable $U_{LAB} \leq U_{MAX}$ the Decision Rule is based on Simple Acceptance in accordance with ISO Guide 98-4: 2012 Clause 8.2, where $U_{MAX} = 30\% (0.3)$ for RF Exposure evaluations. (Measurement uncertainty is not taken into account when stating conformity with a specified requirement.)

For all tests where the applicable $U_{LAB} > U_{MAX}$ the Decision Rule is based on Guarded Acceptance in accordance with ISO Guide 98-4: 2012 Clause 8.3.2, with a guard band equal to $(U_{LAB} - U_{MAX})$, where $U_{MAX} = 30\% (0.3)$ for RF Exposure evaluations. (Test results are adjusted by the value of the guard band to determine conformity with a specified requirement.)

6. DEVICE UNDER TEST

The Contour Plus BLUE blood glucose monitoring system is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertips. The EUT utilizes a BLE module. As the user to antenna separation distance is unspecified, the distance was assumed to be 0mm.

The models 7035 and 7036 are identical from an electrical schematic, board trace layout and enclosure perspective. The models use the same radio. SKU 7036 will be the commercially available SKU while SKU 7035 is the 'Free Goods' SKU.

7. STANDALONE SAR TEST EXCLUSION CONSIDERATIONS

7.1. FCC

SAR test exclusion in accordance with KDB 447498 D01 v6.

The 1-g and 10-g SAR test exclusion thresholds for 100 MHz to 6 GHz at test separation distances ≤ 50 mm are determined by:

$[(\text{max. power of channel, including tune-up tolerance, mW}) / (\text{min. test separation distance, mm})] \cdot [f(\text{GHz})] \leq 3.0$, for 1-g SAR and ≤ 7.5 for 10-g extremity SAR, where

- $f_{(\text{GHz})}$ is the RF channel transmit frequency in GHz
- Power and distance are rounded to the nearest mW and mm before calculation
- The result is rounded to one decimal place for comparison

This test exclusion is applicable only when the minimum test separation distance is ≤ 50 mm and for transmission frequencies between 100 MHz and 6 GHz. When the minimum test separation distance is < 5 mm, a distance of 5 mm is applied to determine SAR test exclusion.

The 1-g and 10-g SAR test exclusion thresholds for 100 MHz to 6 GHz at test separation distances > 50 mm are determined by:

1. $\{[\text{Power allowed at numeric threshold for } 50 \text{ mm}]] + [(\text{test separation distance} - 50 \text{ mm}) \cdot (f(\text{MHz})/150)]\}$ mW, for 100 MHz to 1500 MHz
 - $f_{(\text{MHz})}$ is the RF channel transmit frequency in MHz
2. $\{[\text{Power allowed at numeric threshold for } 50 \text{ mm}]] + [(\text{test separation distance} - 50 \text{ mm}) \cdot 10]\}$ mW, for > 1500 MHz and ≤ 6 GHz

SAR Exclusion Calculation Table for Portable Devices (separation distance < 50 mm)

| Tx | Frequency (MHz) | Avg Output power | | Separation distances (mm) | Calculated Threshold |
|-----|--------------------|------------------|------|------------------------------|-------------------------|
| | | dBm | mW | | |
| BLE | 2480 | 0.00 | 1.00 | 5 | 0.3 |

Conclusion:

The computed values are < 3 ; therefore, the device qualifies for Standalone SAR test exclusion.

END OF TEST REPORT